社论：ADHD 的观察性研究：改用控释型哌甲酯制剂对临床结局和依从性的影响。
Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence.
出版信息
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S235-42. doi: 10.1007/s00787-011-0201-5.
Abstract
Patients with ADHD may have better adherence to treatment with modified-release methylphenidate (MPH-MR) formulations, which are taken once daily, compared with immediate-release (IR) formulations, which need to be taken several times a day. Data on long-term outcomes such as adherence may be lacking from randomised controlled trials as these are usually only short-term. Observational studies, if performed and reported appropriately, can provide valuable long-term data on such outcomes, as well as additional information on effectiveness and efficiency, from a real-life setting. By reviewing previous observational studies that have investigated switching treatment from MPH-IR to MPH-MR, results from a new, naturalistic observational study, the OBSEER study, are put into context. We conclude that, based on observational trial data, switching from MPH-IR to MPH-MR is a valid clinical approach, with the potential for improved clinical outcome and treatment adherence.
摘要
患有注意缺陷多动障碍（ADHD）的患者每日服用一次的缓释型哌醋甲酯（MPH-MR）制剂，其治疗依从性可能优于需要每日多次服用的即刻释放（IR）制剂。由于随机对照试验通常仅为短期试验，因此可能缺乏关于依从性等长期结局的数据。如果进行并适当报告观察性研究，则可以从现实环境中提供有关此类结局的有价值的长期数据，以及关于有效性和效率的其他信息。通过回顾先前研究过从 MPH-IR 转换为 MPH-MR 治疗的观察性研究，将新的自然观察性研究 OBSEER 研究的结果置于上下文中。我们的结论是，基于观察性试验数据，从 MPH-IR 转换为 MPH-MR 是一种有效的临床方法，有可能改善临床结局和治疗依从性。
相似文献
1
Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence.社论：ADHD 的观察性研究：改用控释型哌甲酯制剂对临床结局和依从性的影响。
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S235-42. doi: 10.1007/s00787-011-0201-5.
2
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence.一项关于 ADHA 患者每日一次使用改性释放哌醋甲酯的观察性研究：生活质量、治疗满意度和治疗依从性。
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S257-65. doi: 10.1007/s00787-011-0203-3.
3
An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes.一项关于 ADHD 患者每日一次服用改性释放哌甲酯的观察性研究：既往治疗对 ADHD 症状、其他外化症状和生活质量结局的影响。
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S277-88. doi: 10.1007/s00787-011-0205-1.
4
Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.在三种注意缺陷多动障碍（ADHD）亚型中，对于速释型哌甲酯依从性差的患者，渗透型口服系统哌甲酯疗效更佳。
Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.
5
Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.长效哌甲酯制剂治疗注意缺陷多动障碍：头对头研究的系统评价。
BMC Psychiatry. 2013 Sep 27;13:237. doi: 10.1186/1471-244X-13-237.
6
A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).实验室学校中患有注意力缺陷/多动障碍儿童使用每日一次缓释哌甲酯制剂的比较（Comacs研究）
Pediatrics. 2004 Mar;113(3 Pt 1):e206-16. doi: 10.1542/peds.113.3.e206.
7
An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety.一项关于 ADHA 患者每日一次服用改性释放哌甲酯的观察性研究：对症状和损伤的疗效以及安全性。
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S243-55. doi: 10.1007/s00787-011-0202-4.
8
Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.每日一次服用的盐酸哌甲酯控释片与每日三次服用的哌甲酯在实验室及自然环境中的对比研究。
Pediatrics. 2001 Jun;107(6):E105. doi: 10.1542/peds.107.6.e105.
9
An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate.一项关于注意缺陷多动障碍儿童在改用缓释哌甲酯治疗后反应异质性的观察性研究。
BMC Psychiatry. 2013 Sep 3;13:219. doi: 10.1186/1471-244X-13-219.
10
No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.在注意力缺陷多动障碍儿童的损伤发生率和发生时间方面，渗透型控释口服给药系统-哌甲酯治疗并不优于短效/中效哌甲酯制剂。
Clin Neuropharmacol. 2017 Jan/Feb;40(1):11-15. doi: 10.1097/WNF.0000000000000189.
引用本文的文献
1
Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate.对于使用速释哌甲酯治疗效果欠佳的注意缺陷多动障碍儿童及青少年，缓释哌甲酯的成本效益分析
PLoS One. 2015 May 29;10(5):e0127237. doi: 10.1371/journal.pone.0127237. eCollection 2015.
2
Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers.健康成年志愿者中缓释哌醋甲酯（MPH-MLR）胶囊与速释哌醋甲酯片的稳态生物利用度比较。
Clin Drug Investig. 2014 Nov;34(11):795-805. doi: 10.1007/s40261-014-0234-x.
3
Psychopharmacological treatment in children: always keeping an eye on adherence and ethics.儿童的精神药理学治疗：始终关注依从性和伦理道德。
Eur Child Adolesc Psychiatry. 2013 Aug;22(8):453-5. doi: 10.1007/s00787-013-0445-3.
4
Updates on treatment of attention-deficit/hyperactivity disorder: facts, comments, and ethical considerations.注意缺陷多动障碍治疗的最新进展：事实、评论和伦理考量。
Curr Treat Options Neurol. 2012 Dec;14(6):594-607. doi: 10.1007/s11940-012-0197-2.
本文引用的文献
1
An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety.一项关于 ADHA 患者每日一次服用改性释放哌甲酯的观察性研究：对症状和损伤的疗效以及安全性。
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S243-55. doi: 10.1007/s00787-011-0202-4.
2
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence.一项关于 ADHA 患者每日一次使用改性释放哌醋甲酯的观察性研究：生活质量、治疗满意度和治疗依从性。
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S257-65. doi: 10.1007/s00787-011-0203-3.
3
Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD.生活质量与精神病理特征之间的关系：来自 ADHD 患儿观察性研究的数据。
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S267-75. doi: 10.1007/s00787-011-0204-2.
4
An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes.一项关于 ADHD 患者每日一次服用改性释放哌甲酯的观察性研究：既往治疗对 ADHD 症状、其他外化症状和生活质量结局的影响。
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S277-88. doi: 10.1007/s00787-011-0205-1.
5
Australian national trends in stimulant dispensing: 2002-2009.澳大利亚兴奋剂配给的国家趋势：2002-2009 年。
Aust N Z J Psychiatry. 2011 Apr;45(4):332-6. doi: 10.3109/00048674.2010.543413. Epub 2010 Dec 27.
6
The need for a long-term perspective in child and adolescent psychiatry.儿童与青少年精神病学中长远视角的必要性。
Eur Child Adolesc Psychiatry. 2010 Sep;19(9):687-8. doi: 10.1007/s00787-010-0124-6.
7
Improving medication adherence in chronic pediatric health conditions: a focus on ADHD in youth.提高慢性儿科健康状况下的药物依从性：以青少年注意缺陷多动障碍为例。
Curr Pharm Des. 2010;16(22):2416-23. doi: 10.2174/138161210791959908.
8
Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study.速释型哌甲酯持续使用及依从性的预测因素：一项为期36个月的自然主义研究。
J Child Adolesc Psychopharmacol. 2009 Dec;19(6):673-81. doi: 10.1089/cap.2008.0146.
9
Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications.避免观察性研究中的偏倚：评价科学出版物系列文章第 8 部分。
Dtsch Arztebl Int. 2009 Oct;106(41):664-8. doi: 10.3238/arztebl.2009.0664. Epub 2009 Oct 9.
10
Ethics and observational studies in medical research: various rules in a common framework.医学研究中的伦理与观察性研究：通用框架下的各项规则
Int J Epidemiol. 2009 Aug;38(4):1104-8. doi: 10.1093/ije/dyp164. Epub 2009 Mar 31.
Zotero 插件